News

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Key Takeaways Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and ...
Discover potential risks for Novo Nordisk using Charlie Munger's inversion model. Explore market share, R&D, and why this ...
Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...
GoodRx is joining the GLP-1 action with an announcement Monday to begin selling both of Novo Nordisk's GLP-1 drugs, Ozempic ...
The lawsuit alleges civil violations of the Racketeer Influenced and Corrupt Organizations Act, or RICO, the Connecticut ...
Healthcare stocks trade at a 30-year discount, with XLV showing signs of rebound as Buffett and hedge funds boost exposure.
U.S. stock futures slipped slightly Monday ahead of a summit between U.S. President Donald Trump and Ukraine President Volodymyr Zelensky in Washington in an attempt to arrange a potential peace deal.
Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...
Novo Nordisk surges as Wegovy secures FDA approval for MASH, marking a breakthrough in liver care and expanding its blockbuster reach.
Novo Nordisk has implemented a global hiring freeze covering job roles that are not critical for its business, Reuters writes ...
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...